|
| |
PARC clinical investigation:
Therapeutic Angiogenesis
-
Sponsor: Chiron Corporation
Start Date: July 1999
Enrollment Completed: March 2000
PARC sites are also participating in
A Phase II trial of
adenoviral VEGF-121 in patients with intermittent claudication
Sponsor: GenVec
Enrollment Completed: May 2002
A Phase II trial of gene transfer for therapeutic
angiogenesis in patients with critical limb ischemia
Sponsor: Aventis Gencell
Enrollment: Begins June 2002
Adjunctive Pharmacotherapy
Novel Anti-platelet
therapies
Novel anti-thrombotics
|
